Effect of Pioglitazone on HIV-1 Related Lipoatrophy: a Randomized, Double Blind, Placebo-Controlled Trial in 130 Patients
A Randomized, Phase 3, Double Blind, Multicentre Trial, Evaluating the Effect of Pioglitazone Versus Placebo on Change in Lipoatrophy in HIV- 1 Infected Patients Treated With Stable Antiretroviral Therapy for at Least 6 Months.ANRS 113 LIPIOT Study
Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from French National Agency for Research on AIDS and Viral Hepatitis
- Chronic Hepatitis C · Phase PHASE3 · Jul 2012
- HBe Negative Chronic Hepatitis B · Phase PHASE3 · Dec 2008
- HIV Infections · Phase PHASE1/PHASE2 · Oct 2008
- Hepatitis B · Phase PHASE3 · Jul 2008
- Hepatitis C, Chronic · Phase PHASE3 · Dec 2006
See all terminations from French National Agency for Research on AIDS and Viral Hepatitis
Listed as NCT00148850, this PHASE3 trial focuses on HIV Infections and HIV-Associated Lipodystrophy Syndrome and remains terminated or withdrawn. Sponsored by French National Agency for Research on AIDS and Viral Hepatitis, it has been updated 5 times since 2003, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE3
First recorded
Feb 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- French National Agency for Research on AIDS and Viral Hepatitis
- Takeda
For direct contact, visit the study record on ClinicalTrials.gov .